BRIEF-Genflow Biosciences Says Repeat Administration Of SIRT6 Shows Excellent Safety & Tolerability Profile

Reuters2025-10-10

Oct 10 (Reuters) - Genflow Biosciences PLC GENF.L:

GENFLOW BIOSCIENCES PLC - REPEAT ADMINISTRATION OF SIRT6 SHOWS EXCELLENT SAFETY AND TOLERABILITY PROFILE

Source text: ID:nRSJ8229Ca

Further company coverage: GENF.L

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2574914493?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-10 14:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574914493","market":"us","top_or_hot":-1,"title":"BRIEF-Genflow Biosciences Says Repeat Administration Of SIRT6 Shows Excellent Safety & Tolerability Profile","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Genflow Biosciences Says Repeat Administration Of SIRT6 Shows Excellent Safety &amp; Tolerability Profile</title></head><body><p><span>Oct 10 (Reuters)</span><span> - </span>Genflow Biosciences <a href=\"https://laohu8.com/S/PLC\">PLC</a> <span>GENF.L</span>:</p><ul><li><p><a href=\"https://laohu8.com/S/GENF.UK\">GENFLOW BIOSCIENCES PLC</a> - REPEAT ADMINISTRATION OF SIRT6 SHOWS EXCELLENT SAFETY AND TOLERABILITY PROFILE</p></li></ul><p>Source text: <span>ID:nRSJ8229Ca</span></p><p>Further company coverage: <span>GENF.L</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Genflow Biosciences Says Repeat Administration Of SIRT6 Shows Excellent Safety & Tolerability Profile</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Genflow Biosciences Says Repeat Administration Of SIRT6 Shows Excellent Safety & Tolerability Profile\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-10 14:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Genflow Biosciences Says Repeat Administration Of SIRT6 Shows Excellent Safety &amp; Tolerability Profile</title></head><body><p><span>Oct 10 (Reuters)</span><span> - </span>Genflow Biosciences <a href=\"https://laohu8.com/S/PLC\">PLC</a> <span>GENF.L</span>:</p><ul><li><p><a href=\"https://laohu8.com/S/GENF.UK\">GENFLOW BIOSCIENCES PLC</a> - REPEAT ADMINISTRATION OF SIRT6 SHOWS EXCELLENT SAFETY AND TOLERABILITY PROFILE</p></li></ul><p>Source text: <span>ID:nRSJ8229Ca</span></p><p>Further company coverage: <span>GENF.L</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GENF.UK","symbol_name":"GENFLOW BIOSCIENCES PLC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nFWN3VR0XH:1","article_id":"2574914493","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2574914493","pubTimestamp":1760077625,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Genflow Biosciences Says Repeat Administration Of SIRT6 Shows Excellent Safety & Tolerability ProfileOct 10 (Reuters) - Genflow Biosciences PLC GENF.L:GENFLOW BIOSCIENCES PLC - REPEAT ADMINISTRA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GENF.UK":"GENFLOW BIOSCIENCES PLC","BK5083":"生物科技"},"translate_title":"简介-Genflow Biosciences表示SIRT6的重复给药显示出出色的安全性和耐受性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GENF.UK":0.9},"content_text":"BRIEF-Genflow Biosciences Says Repeat Administration Of SIRT6 Shows Excellent Safety & Tolerability ProfileOct 10 (Reuters) - Genflow Biosciences PLC GENF.L:GENFLOW BIOSCIENCES PLC - REPEAT ADMINISTRATION OF SIRT6 SHOWS EXCELLENT SAFETY AND TOLERABILITY PROFILESource text: ID:nRSJ8229CaFurther company coverage: GENF.L ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2574914493","isCrawlerRequest":true}